Jump to Header Jump to Main Content Jump to Footer

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab

Ali A Habib


A Study On:

  • Generalized Myasthenia Gravis
  • Brain - Neurologic/ Psychologic

Status:

  • Open

Eligibility

18 Years and older (Adult, Older Adult)

Interested in joining this trial?

Official Title

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Details

Primary Outcome Measures: Record number of participants with adverse events.

Secondary Outcome Measures :
1. The MG-ADL profile provides an assessment of MG symptom severity and measures 8 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the ADL score. The ADL score can range from 0 (least severe) to 24 (most severe).

2. The QMG test is a standardized quantitative strength scoring system and measures 13 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the QMG score. The QMG score can range from 0 (least severe) to 39 (most severe).


Eligibility

You can join if...

Inclusion Criteria:
. Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan study

Exclusion Criteria:

. With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)

Get in touch with our study team